[{"id":"e0d150b0-e8da-41e4-9df7-1fc41df6dcb0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02484404","created_at":"2021-01-17T17:57:31.886Z","updated_at":"2024-07-02T16:34:36.994Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...","source_id_and_acronym":"NCT02484404","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • HER-2 • BRAF • ALK • PGR • BRCA1 • BRCA2","pipe":" | ","alterations":" BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • ALK translocation • BRCA1 mutation + BRCA2 mutation","tags":["EGFR • HER-2 • BRAF • ALK • PGR • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • ALK translocation • BRCA1 mutation + BRCA2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)"],"overall_status":"Recruiting","enrollment":" Enrollment 384","initiation":"Initiation: 06/29/2015","start_date":" 06/29/2015","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-06-07"},{"id":"9b5a5f0f-bb8b-4bc3-bf51-2de472f960ac","acronym":"COMETABreast","url":"https://clinicaltrials.gov/study/NCT03205761","created_at":"2021-01-18T15:49:07.908Z","updated_at":"2024-07-02T16:34:37.740Z","phase":"Phase 2","brief_title":"Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer","source_id_and_acronym":"NCT03205761 - COMETABreast","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA1 mutation + BRCA2 mutation • BRCA mutation • PGR expression • BRCA1 promoter methylation","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA1 mutation + BRCA2 mutation • BRCA mutation • PGR expression • BRCA1 promoter methylation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 10/23/2017","start_date":" 10/23/2017","primary_txt":" Primary completion: 12/15/2022","primary_completion_date":" 12/15/2022","study_txt":" Completion: 12/15/2022","study_completion_date":" 12/15/2022","last_update_posted":"2024-06-06"},{"id":"7d4bee37-66f9-444a-b255-8785fecda7ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT04182516","created_at":"2021-01-18T20:23:35.888Z","updated_at":"2024-07-02T16:35:08.443Z","phase":"Phase 1","brief_title":"Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT04182516","lead_sponsor":"Nerviano Medical Sciences","biomarkers":" HER-2 • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA1 mutation + BRCA2 mutation","tags":["HER-2 • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA1 mutation + BRCA2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NMS-293"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/25/2019","start_date":" 11/25/2019","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-04-22"},{"id":"8ba4b2c4-2d3e-460e-9a2f-77116f701fa8","acronym":"S1513","url":"https://clinicaltrials.gov/study/NCT02890355","created_at":"2021-01-18T14:11:10.280Z","updated_at":"2024-07-02T16:35:11.214Z","phase":"Phase 2","brief_title":"FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT02890355 - S1513","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • CEACAM5","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD • HRD + BRCA1 mutation • BRCA1 mutation + BRCA2 mutation","tags":["BRCA1 • BRCA2 • HRD • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD • HRD + BRCA1 mutation • BRCA1 mutation + BRCA2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • veliparib (ABT-888) • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 123","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2024-04-05"},{"id":"7723f8fb-6980-474d-9045-89aafd5d0f1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00823654","created_at":"2021-01-18T03:07:54.140Z","updated_at":"2024-07-02T16:35:21.003Z","phase":"","brief_title":"Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations","source_id_and_acronym":"NCT00823654","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 overexpression • BRCA1 mutation + BRCA2 mutation","tags":["HER-2 • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 overexpression • BRCA1 mutation + BRCA2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 609","initiation":"Initiation: 01/01/2009","start_date":" 01/01/2009","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-02-02"},{"id":"d65863ad-7efa-4719-a1a1-47fc18cfeebf","acronym":"iRetroBC","url":"https://clinicaltrials.gov/study/NCT06131424","created_at":"2023-11-14T22:15:41.310Z","updated_at":"2024-07-02T16:35:22.353Z","phase":"","brief_title":"NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients","source_id_and_acronym":"NCT06131424 - iRetroBC","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER • PIK3CA • BRCA1 • PTEN • ATM • AKT1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative • PIK3CA mutation • HER-2 expression • ATM mutation • PALB2 mutation • ESR1 mutation • BRCA1 mutation + BRCA2 mutation","tags":["HER-2 • ER • PIK3CA • BRCA1 • PTEN • ATM • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative • PIK3CA mutation • HER-2 expression • ATM mutation • PALB2 mutation • ESR1 mutation • BRCA1 mutation + BRCA2 mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 2700","initiation":"Initiation: 03/04/2024","start_date":" 03/04/2024","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-01-24"},{"id":"24b097d3-25d4-41e0-b751-9c63b41a00fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT00579488","created_at":"2021-03-08T14:52:11.962Z","updated_at":"2024-07-02T16:35:29.295Z","phase":"","brief_title":"Clinical Significance of Germline BRCA Mutations","source_id_and_acronym":"NCT00579488","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13320","initiation":"Initiation: 07/01/1996","start_date":" 07/01/1996","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-11-14"},{"id":"b6e1732a-94ba-4987-89c6-fdaa0b335f2b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05404334","created_at":"2022-06-03T11:55:35.300Z","updated_at":"2024-07-02T16:36:09.313Z","phase":"","brief_title":"of Androgen Receptor Expression in Breast Cancer With or Without BRCA Mutation","source_id_and_acronym":"NCT05404334","lead_sponsor":"Banaras Hindu University","biomarkers":" BRCA1 • BRCA2 • AR • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • AR expression • BRCA1 mutation + BRCA2 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • AR • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • AR expression • BRCA1 mutation + BRCA2 mutation • BRCA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-06-06"},{"id":"21a05a22-e175-49ad-b464-b0c44646b479","acronym":"CHRISTELLE","url":"https://clinicaltrials.gov/study/NCT04222465","created_at":"2021-01-18T20:33:05.634Z","updated_at":"2024-07-02T16:36:22.431Z","phase":"","brief_title":"Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer Patients","source_id_and_acronym":"NCT04222465 - CHRISTELLE","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation"],"overall_status":"Completed","enrollment":" Enrollment 207","initiation":"Initiation: 03/19/2020","start_date":" 03/19/2020","primary_txt":" Primary completion: 11/13/2020","primary_completion_date":" 11/13/2020","study_txt":" Completion: 11/13/2020","study_completion_date":" 11/13/2020","last_update_posted":"2021-10-26"},{"id":"cbf09b9b-a2c0-4dc6-a145-f3dcbb85965c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01623349","created_at":"2021-01-18T06:57:53.787Z","updated_at":"2024-07-02T16:36:34.794Z","phase":"Phase 1","brief_title":"Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer","source_id_and_acronym":"NCT01623349","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BRCA1 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation","tags":["BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Piqray (alpelisib) • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 118","initiation":"Initiation: 09/01/2012","start_date":" 09/01/2012","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2021-02-10"},{"id":"6038dbc0-ffd8-4c83-8918-bd2e2c956181","acronym":"PREDICT","url":"https://clinicaltrials.gov/study/NCT03082976","created_at":"2021-01-18T15:11:15.812Z","updated_at":"2024-07-02T16:36:43.129Z","phase":"","brief_title":"Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region","source_id_and_acronym":"NCT03082976 - PREDICT","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation • BRCA mutation"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 07/16/2017","start_date":" 07/16/2017","primary_txt":" Primary completion: 07/24/2019","primary_completion_date":" 07/24/2019","study_txt":" Completion: 07/24/2019","study_completion_date":" 07/24/2019","last_update_posted":"2020-07-16"},{"id":"b753693a-72f0-4da7-be1b-b299d0ad8956","acronym":"FLABRA","url":"https://clinicaltrials.gov/study/NCT02984423","created_at":"2021-01-18T14:41:20.658Z","updated_at":"2024-07-02T16:36:43.377Z","phase":"","brief_title":"FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study","source_id_and_acronym":"NCT02984423 - FLABRA","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation + BRCA2 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation + BRCA2 mutation • BRCA mutation"],"overall_status":"Completed","enrollment":" Enrollment 471","initiation":"Initiation: 12/27/2016","start_date":" 12/27/2016","primary_txt":" Primary completion: 06/30/2019","primary_completion_date":" 06/30/2019","study_txt":" Completion: 06/30/2019","study_completion_date":" 06/30/2019","last_update_posted":"2020-07-10"},{"id":"59c77bee-74da-4081-96e3-d3c6eaa72a3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02514499","created_at":"2021-01-18T12:09:00.478Z","updated_at":"2024-07-02T16:36:57.766Z","phase":"","brief_title":"Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study","source_id_and_acronym":"NCT02514499","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation • BRCA1 negative","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation • BRCA1 negative"],"overall_status":"Completed","enrollment":" Enrollment 350","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 10/01/2018","primary_completion_date":" 10/01/2018","study_txt":" Completion: 10/01/2018","study_completion_date":" 10/01/2018","last_update_posted":"2019-07-24"},{"id":"3d44efbf-1548-46dd-ae4f-9be7440f6e5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00588263","created_at":"2021-01-18T02:10:16.832Z","updated_at":"2024-07-02T16:37:13.816Z","phase":"","brief_title":"Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer","source_id_and_acronym":"NCT00588263","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2000","start_date":" 07/01/2000","primary_txt":" Primary completion: 07/01/2018","primary_completion_date":" 07/01/2018","study_txt":" Completion: 07/01/2018","study_completion_date":" 07/01/2018","last_update_posted":"2018-02-19"}]